Proposed LCD DL39297: Off-label Use of Rituximab and Rituximab Biosimilars — NGS
Policy LCD-DL39297 · Oncology
Impact of proposed LCD on Rituximab billing practices.
Code intelligence
Q5119 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code Q5119.
Elevated code riskView HCPCS detail
Signal breakdown
3 shown · 3 total in platform
Risk: Elevated
0
Critical
0%
1
High
33%
2
Routine
67%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
LCD L39297: Off-label Use of Rituximab and Rituximab Biosimilars — NGS
Policy LCD-L39297 · Oncology
Off-label Rituximab use may impact Medicare billing.
LCD L38920: Off-label Use of Rituximab and Rituximab Biosimilars — CGS
Policy LCD-L38920 · Oncology
Prepare for billing changes on Rituximab off-label use.
Audit documentation
Building an audit file that includes Q5119?
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Oncology audit pack — $349One-time purchase · not a subscription